PUBLISHER: The Business Research Company | PRODUCT CODE: 1274414
PUBLISHER: The Business Research Company | PRODUCT CODE: 1274414
“Therapeutic BCG Vaccines Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on therapeutic bcg vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for therapeutic bcg vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The therapeutic bcg vaccines market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.
Major players in the therapeutic BCG vaccines market are Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, BB-NCIPD Ltd., Biomed Lublin S.A., PowderJect Pharmaceuticals, Microgen, Taj Pharma Ltd. and BioFarma.
The global therapeutic BCG vaccines market is expected to grow from $50.73 billion in 2022 to $53.18 billion in 2023 at a compound annual growth rate (CAGR) of 4.82%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The therapeutic BCG vaccines market is expected to grow to $65.62 billion in 2027 at a CAGR of 5.40%.
The therapeutic BCG vaccines market consists of sales of vectors, peptides, proteins, DNA, and dendritic cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Therapeutic BCG vaccine refers to a vaccine that offers defense against TB, also referred to as tuberculosis. The therapeutic BCG vaccine, which stands for the Bacillus Calmette-Guerin vaccine, is not a part of the standard NHS vaccination schedule. Only one dose of the BCG vaccine should be administered in a lifetime.
Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2022. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The two major types of therapeutic BCG vaccines are therapy BCG and immune BCG. Therapy BCG refers to a kind of intravesical immunotherapy that aids the immune system's destruction of cancer cells and is frequently used to treat bladder cancer in its early stages. By demographics, BCG vaccines can be used on pediatrics and adults. These are used by several end-users, such as hospitals, clinics, and other end-users.
The rising number of tuberculosis (TB) cases worldwide will propel the growth of the therapeutic BCG vaccine market going forward. Tuberculosis (TB) is an infectious illness that can be potentially dangerous and primarily impacts the lungs. People can contract tuberculosis from one another by coughing or sneezing small droplets of bacteria into the air. BCG vaccines are used to stimulate the immune system to fight infection but do not cause TB since the germs are weak. It consistently offers protection against the most dangerous types of TB, like adolescent TB meningitis. The BCG vaccine protects against tuberculosis which helps to fight against infection, hence the usage of therapeutic BCG vaccines increased. For instance, in October 2022, according to a report published by the World Health Organization, a specialized agency of the United Nations responsible for international public health, 10.6 million people were predicted to have contracted tuberculosis (TB) in 2021, an increase of 4.5% from 2020, and 1.6 million died from TB (including 187,000 HIV-positive individuals). Therefore, the rising number of tuberculosis (TB) cases worldwide is driving the growth of the therapeutic BCG vaccine market.
Strategic partnerships have emerged as a key trend gaining popularity in the therapeutic BCG vaccine market. Major companies operating in the therapeutic BCG vaccine market are focused on collaborating with other key players to sustain their position in the market. For instance, in July 2021, Zendal, a Spain-based pharmaceutical company, partnered with a US-based not-for-profit organization to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials. The only live, attenuated Mycobacterium tuberculosis vaccine currently being developed is MTBVAC. It is now being developed to prevent tuberculosis in adults and adolescents, for whom there is currently no effective vaccination, and as a more potent and potentially long-lasting vaccine than BCG for infants. This statement coincides with the rapid development of several vaccinations to guard against COVID-19.
In February 2022, Sanofi S.A., a France-based multinational pharmaceutical and healthcare company, acquired Amunix for an undisclosed amount. This acquisition provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver conditionally activated biologics of the next generation. The technology platform supports Sanofi's efforts to accelerate and expand its contributions to cutting-edge therapies for oncology patients, with about 20 compounds presently in development. It is a perfect addition to Sanofi's existing R&D platforms. Amunix is a US-based immuno-oncology company intended to discover, design, and develop novel biologics, proteins, and peptide therapeutics.
The countries covered in the therapeutic BCG vaccines market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The therapeutic BCG vaccines market research report is one of a series of new reports from The Business Research Company that provides therapeutic BCG vaccines market statistics, including therapeutic BCG vaccines industry global market size, regional shares, competitors with a therapeutic BCG vaccines market share, detailed therapeutic BCG vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic BCG vaccines industry. This therapeutic BCG vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.